Adaptate establishes Scientific Advisory Board to progress therapeutic antibodies portfolio

UK immunotherapy company, Adaptate Biotherapeutics, has established a Scientific Advisory Board (SAB) to progress its portfolio of therapeutic antibodies.

Professor Adrian Hayday will chair the expert team with other key appointments comprising Professor Gillian Griffiths, Dr John Haurum, Dr Jessica Strid and Professor Sally Ward.

Professor Hayday is a scientific founder of Adaptate and brings with him a lifetime of research experience as one of the leading academics to uncover the unique properties of T cells.

Over the course of his career, he has authored over 200 papers and received many awards for this work. Having also co-founded GammaDelta Therapeutics and provided expert advice for many institutions such as Institut Pasteur, the Max Planck Institute and Kyoto University, Professor Hayday is currently Professor of Immunobiology at King’s College London and Assistant Research Director at the Francis Crick Institute.

Professor Hayday is joined by leading experts in areas critical to the future development of Adaptate with each bringing a wealth of experience and knowledge to the company.

Professor Gillian Griffiths, Professor of Cell Biology and Immunology at the University of Cambridge and former Director of the Cambridge Institute for Medical Research, was one of the first to show that cytotoxic T cells have specialised mechanisms of secretion and has gone on to identify the molecular mechanisms that underly such processes. Professor Griffiths is an elected Fellow of the Royal Society.

Dr John Haurum is a Non-executive Director of a number of European biotech companies including Synklino, Neophore, Storm, Agomab, Synact and an advisor to Novo Seeds. As Chief Executive of UK-based F-star, he built a successful biotech company that initiated two clinical trials in oncology and generated more than €200M in non-dilutive revenue.

Dr Jessica Strid is a reader in Cellular Immunology at Imperial College London. She previously worked in Adrian Hayday’s research group at King’s College London and Cancer Research UK and was awarded a Wellcome Trust New Investigator Award, going on to win a prestigious Wellcome Trust Investigator Award in 2019.

Her studies focus on immune-surveillance at epithelial body surface tissues and the role of tissue resident immune cells in regulating epithelial cell homeostasis, repair and carcinogenesis.

Professor Sally Ward is currently Professor of Molecular Immunology and Director of Translational Immunology at the University of Southampton’s Centre for Cancer Immunology as well as Vice President of the Antibody Society.

From 1990-2020, she was on the faculty at UT Southwestern Medical Center in Dallas, followed by Texas A&M University. Her research focuses on a highly interdisciplinary approach to generating effective therapeutics for autoimmunity and cancer which has led to several technologies that are currently in the clinic.

Dr Natalie Mount, CEO of Adaptate Biotherapeutics, said: “Adaptate’s portfolio of therapeutic antibodies harnessing the power of gamma delta T cells represents next generation immunotherapy.

“The newly appointed SAB will be instrumental in contributing to the company’s unique, targeted approach as we progress to the next phase in our development.

“We are delighted to welcome such distinguished scientists and antibody developers to our team – their collective experience will be invaluable.”

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Blenrep becomes first anti-BCMA approved globally

GlaxoSmithKline (GSK) has secured US approval for Blenrep (belantamab mafodotin-blmf) as a monotherapy treatment for adult patients with relapsed or refractory multiple myeloma. This indication...

Joint investment sees UK gov secure pipeline of coronavirus vaccine candidate

The UK government and biotech Valneva have jointly invested in a Scottish facility to bolster vaccine manufacturing capacity. The multi-million-pound investment will allow the government...

Redx out-licenses porcupine inhibitor to AstraZeneca

UK drug discovery and development company, Redx Pharma, has signed a significant out-licensing agreement for its porcupine inhibitor, RXC006, with AstraZeneca. AstraZeneca will take RXC006...

New Chief Medical Officer for Valneva

Valneva, a specialty vaccine company based in France, has appointed Juan Carlos Jaramillo, as Chief Medical Officer and member of the Management Board. Starting 1st...

Majority of top pharma firms report YoY growth in 2019 – data

In 2019, 17 of the top twenty major pharmaceutical players reported year-on-year revenue growth, according to GlobalData. “One winner was Takeda, which saw more than...

Related news

ACG promotes Susheel Pillai as the new CEO for Inspection Business

ACG, a leading supplier of fully integrated solutions to the global pharmaceutical and nutraceutical industry, today announced the promotion of Susheel Pillai as the new...

Blenrep becomes first anti-BCMA approved globally

GlaxoSmithKline (GSK) has secured US approval for Blenrep (belantamab mafodotin-blmf) as a monotherapy treatment for adult patients with relapsed or refractory multiple myeloma. This indication...

Joint investment sees UK gov secure pipeline of coronavirus vaccine candidate

The UK government and biotech Valneva have jointly invested in a Scottish facility to bolster vaccine manufacturing capacity. The multi-million-pound investment will allow the government...

Redx out-licenses porcupine inhibitor to AstraZeneca

UK drug discovery and development company, Redx Pharma, has signed a significant out-licensing agreement for its porcupine inhibitor, RXC006, with AstraZeneca. AstraZeneca will take RXC006...